Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(1 year, 2 days from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6303661 | BOEHRINGER INGELHEIM | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr, 2017
(7 years ago) | |
US7459428 | BOEHRINGER INGELHEIM | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
US7078381 | BOEHRINGER INGELHEIM | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
US6890898 | BOEHRINGER INGELHEIM | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
US8178541 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(8 months ago) | |
US8119648 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(8 months ago) | |
US7407955 (Pediatric) | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Nov, 2025
(1 year, 6 months from now) | |
US8883805 | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
Nov, 2025
(1 year, 6 months from now) | |
US8883805 (Pediatric) | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
May, 2026
(2 years from now) | |
US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(3 years from now) | |
US9173859 | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
May, 2027
(3 years from now) | |
US11033552 | BOEHRINGER INGELHEIM | DPP IV inhibitor formulations |
May, 2027
(3 years from now) | |
US8673927 (Pediatric) | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
Nov, 2027
(3 years from now) | |
US11033552 (Pediatric) | BOEHRINGER INGELHEIM | DPP IV inhibitor formulations |
Nov, 2027
(3 years from now) | |
US10034877 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Aug, 2029
(5 years from now) | |
US9486526 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Aug, 2029
(5 years from now) | |
US10034877 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Feb, 2030
(5 years from now) | |
US9486526 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Feb, 2030
(5 years from now) | |
US8846695 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Jun, 2030
(6 years from now) | |
US8846695 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Dec, 2030
(6 years from now) | |
US8853156 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Mar, 2031
(6 years from now) | |
US8853156 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Sep, 2031
(7 years from now) |
Tradjenta is owned by Boehringer Ingelheim.
Tradjenta contains Linagliptin.
Tradjenta has a total of 23 drug patents out of which 6 drug patents have expired.
Expired drug patents of Tradjenta are:
Tradjenta was authorised for market use on 02 May, 2011.
Tradjenta is available in tablet;oral dosage forms.
Tradjenta can be used as method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin, method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and who are ineligible for metformin therapy by administering linagliptin, method of treating type 2 diabetes mellitus by administering linagliptin in combination with insulin (with or without metformin and/or pioglitazone), method of treating type 2 diabetes mellitus by administering linagliptin, treatment of type 2 diabetes mellitus in a patient with renal impairment and for whom metformin therapy is inappropriate by administering linagliptin without dose adjustment, treatment of type 2 diabetes mellitus, method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and for whom metformin therapy is inappropriate by administering linagliptin, method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor.
Drug patent challenges can be filed against Tradjenta from 20 December, 2025.
The generics of Tradjenta are possible to be released after 05 September, 2031.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-295) | Jun 20, 2026 |
Pediatric Exclusivity(PED) | Dec 20, 2026 |
M(M-252) | Mar 30, 2023 |
M(M-258) | Jul 03, 2022 |
M(M-121) | Aug 13, 2015 |
New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
M(M-118) | Aug 13, 2015 |
Drugs and Companies using LINAGLIPTIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 02 May, 2011
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with insulin (...
Dosage: TABLET;ORAL